


FRONT / CLOSE



**PATIENT CARD**

Name: \_\_\_\_\_





**IMPORTANT SAFETY**

Information For Patients  
Receiving Treatment With  
**TECVAYLI® or TALVEY®**

Carry this card with you at all times.  
**SHOW THIS CARD** to any healthcare professional involved in your care and if you go to the A&E department.

**Johnson & Johnson**  
Johnson & Johnson International (Singapore) Pte Ltd  
No 2, Science Park Drive, #07-13, Ascent, Science Park 1, Singapore 118222

95mm (w) x 60mm(h)


BACK / CLOSE

**FOR HEALTHCARE PROFESSIONALS**

**IMPORTANT SAFETY INFORMATION YOU SHOULD KNOW:**  
TECVAYLI® and TALVEY® therapy can cause cytokine release syndrome (CRS) or neurologic toxicity, including Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) which may be fatal or life-threatening. CRS may involve multiple organ systems.



TECVAYLI® Prescribing Information



TALVEY® Prescribing Information

Complete the Patient Card based on the drug prescribed and provide the Patient Card to the patient.

This Patient has received: (Please check one)  **TECVAYLI®** (teclistamab)  **TALVEY®** (talquetamab)

Name of Treating Physician: \_\_\_\_\_

Treating Physician's Clinic Contact Number: \_\_\_\_\_

Hospital Name: \_\_\_\_\_

Hospital Phone Number: \_\_\_\_\_

Dosing Schedule: (Please check one)  **Weekly Dosing**  **Bi-Weekly Dosing**

Dates of Injections:

Step-up Dose 1: \_\_\_\_\_ Step-up Dose 2: \_\_\_\_\_


Step-up Dose 3: \_\_\_\_\_ First Treatment Dose: \_\_\_\_\_

\*Applies only if patient is receiving TALVEY® at a treatment dose of 0.8 mg/kg  
For more information about TECVAYLI® or TALVEY®, please scan the QR code for the Singapore Package Insert  
Tecvayli & Talvey Patient Card Version 1. This document has been approved by HSA as of 15-Nov-2024

EM-171289

INSIDE / OPEN


**FOR THE PATIENT**



Call your healthcare professional or get emergency help right away if you recognize any of these symptoms:


Symptoms of Cytokine Release Syndrome (CRS):	Symptom of neurologic toxicity including ICANS:	
<ul style="list-style-type: none"> <li>Fever (38°C or higher)</li> <li>Difficulty breathing</li> <li>Chills</li> <li>Fast heartbeat</li> <li>Dizziness or light-headedness</li> <li>Confusion or restlessness</li> <li>Headache</li> <li>Low blood pressure</li> </ul>	<ul style="list-style-type: none"> <li>Headache</li> <li>Feeling confused or disoriented</li> <li>Being less alert or aware</li> <li>Feeling sleepy</li> <li>Low energy (lethargy)</li> <li>Slowness or difficulty thinking</li> <li>Seizures</li> <li>Memory Loss</li> <li>Jerking movements</li> <li>Rigid muscles</li> </ul>	<ul style="list-style-type: none"> <li>Feeling restless</li> <li>Numbness and tingling (feeling like "pins and needles")</li> <li>Trouble speaking or writing</li> <li>Muscle spasms</li> <li>Shaking (tremors)</li> <li>Problems walking</li> <li>Hearing Loss</li> <li>Muscle weakness in your body or face</li> <li>Double vision</li> <li>Burning, throbbing or stabbing pain</li> </ul>


You should always ask your doctor about taking other medications while taking TECVAYLI® or TALVEY®.



**IMPORTANT TO REMEMBER:** Stay close to the location where you received your therapy for at least 2 days for daily monitoring after administration of all doses within the step-up dosing schedule. If you have any of these symptoms, call your doctor or seek emergency medical attention right away! These are not all of the possible symptoms of TECVAYLI® or TALVEY®. Tell your doctor if you have any symptom that bothers you or does not go away.

**Johnson & Johnson**  
Johnson & Johnson International (Singapore) Pte Ltd  
No 2, Science Park Drive, #07-13, Ascent, Science Park 1, Singapore 118222





95mm (w) x 119mm(h)